

MORGANTOWN PULMONARY ASSOCIATES, P.C.

*Roger A. Abrahams, M.D., FCCP
Andrzej J. Jaworski, M.D., FCCP, D.A.B.S.M.*

*1265 Pineview Drive
Morgantown, WV 26505*

Phone 304-598-2336
Fax 304-598-3717

Pulmonary Diseases
Critical Care
Sleep Medicine
Occupational Lung Disease



CURRICULUM VITAE

NAME: ROGER A. ABRAHAMS, M.D., F.C.C.P.

DATE OF BIRTH:

HOME ADDRESS:

BUSINESS ADDRESS: Morgantown Pulmonary Associates, P.C. &
Morgantown Pulmonary Clinical Research
1265 Pineview Drive
Morgantown, WV 26505

2016 MAR 15 AH10: 29
OWCP/DCMWC
DIRECTOR'S OFFICE

GRADUATE TRAINING: Fellowship in Pulmonary Medicine 1983-1985
Saint Vincent Hospital
Major Affiliate: University of
Massachusetts Medical School

Residency in Internal Medicine 1981-1983
Stamford Hospital, Stamford, Connecticut
Major Affiliate: New York Medical College
Chief Resident: 8/82 - 1/83

Internship in Internal Medicine 1979-1980
Long Island Jewish Medical Center
New Hyde Park, NY
Major Affiliate: State University of
New York at Stonybrook

PROFESSIONAL EXPERIENCE: Private Practice 8/87-Present
President
Morgantown Pulmonary Associates, P.C.
1265 Pineview Drive
Morgantown, WV 26505

Clinical Research Morgantown Pulmonary Clinical Research Owner 1265 Pineview Drive Morgantown WV 26505	1995-Present
Speaker for GSK	2009-2015
Clinical Assistant Professor of Medicine West Virginia University Department of Medicine Section of Pulmonary and Critical Care Robert C. Byrd Health Sciences Center Morgantown, WV 26506-9156	7/01-Present
NIOSH Certified B-Reader	1986-Present
Executive Committee Monongalia General Hospital 1200 J. D. Anderson Drive Morgantown, WV 26505	11/98-10/2009
Chief, Section of Pulmonary Medicine Monongalia General Hospital	12/00-2010
President Medical Staff Health South Regional Rehabilitation Hospital 1160 Van Voorhis Road Morgantown, WV 26505	1/06-1/07
Vice President Medical Staff Health South Regional Rehabilitation Hospital	1/05-1/06
Executive Committee Health South Regional Rehabilitation Hospital	1994-1998
Chief of Department of Medicine Monongalia General Hospital	1/90-1/92
Private Practice Pulmonary and Occupational Lung Disease 1197 Van Voorhis Road Morgantown, WV 26505	4/87-8/87
Medical Director West Virginia Society for Respiratory Therapy, Chapter II	1987-1988

Private Practice 1985-1987
Pulmonary and Occupational Lung Disease
Internal Medicine Associates, Inc.
99 J. D. Anderson Drive
Morgantown, WV 26505

Medical Director 1986-1987
Pulmonary Rehabilitation
Monongalia General Hospital

Prior to 1986 upon Request

PRESENTATIONS/PUBLICATIONS

(See attachment)

Abstract, ACCP (2014) American College of Chest Physicians - CHEST 2014. Combined Use of Olodaterol Respimat® and Tiotropium HandiHaler® Shows Additional Lung Function Improvement in COPD Compared with Tiotropium: Results from Two Randomized, Double-blind Studies.
Richard ZuWallack, *Lisa Allen, *Gemzel Hernandez-Martinez, *Naitee Ting, **Roger Abrahams**.

Abstract, ERS (2014) European Respiratory Society - 24th Annual Congress. Safety of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat® in chronic obstructive pulmonary disease in two 1-year studies.
Roland Buhl, **Roger Abrahams**, Leif Bjermer, Eric Derom, Matjaž Fležar, Jacques Hébert, Antony Veale, *Lars Grönke, *Alan Hamilton, *Kay Tetzlaff *Lawrence Korducki, *Holger Huisman, *Stella Waitere-Wijker, Lorcan McGarvey

Abstract, ACCP (2014) American College of Chest Physicians - CHEST 2014. Pooled Safety Analysis of Once-Daily Tiotropium and Olodaterol Fixed-Dose Combination via the Respimat® in Patients with Chronic Obstructive Pulmonary Disease: Two 1-Year Studies.
Roland Buhl, **Roger Abrahams**, Leif Bjermer, Eric Derom, Matjaž Fležar, Jacques Hébert, Antony Veale, *Lars Groenke, *Kay Tetzlaff *Lawrence Korducki, *Holger Huisman, *Stella Waitere-Wijker, Lorcan McGarvey

Poster, BTS (2014) British Thoracic Society Winter Meeting 2014. Safety of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat in chronic obstructive pulmonary disease in two 1-year studies.

Roland Buhl, **Roger Abrahams**, Leif Bjermer, Eric Derom, Matjaž Fležar, Jacques Hébert, Antony Veale, *Lars Groenke, *Alan Hamilton, *Kay Tetzlaff, *Lawrence Korducki, *Holger Huisman, *Stella Waitere-Wijker, Lorcan McGarvey

Abstract presentation CHEST 2014, Austin, TX, 10/29/14: Safety of the Combination of Olodaterol Respimat[®] and Tiotropium HandiHaler[®] Compared with Tiotropium: Results from Two Replicate 12-Week Studies. **Roger Abrahams**,¹ Lisa Allen,² Gemzel Hernandez,² Naitee Ting,² Richard ZuWallack³

ZuWallack R, Allen L, Hernandez G, Ting N, **Abrahams R**, Efficacy and safety of combining olodaterol Respimat[®] and tiotropium HandiHaler[®] in patients with COPD: results of two randomized, double-blind, active-controlled studies.

International Journal of Chronic Obstructive Pulmonary Disease. October 2014, Volume 2014:9, Pages 1133—1144

Oral Abstract presentation at the Asian Pacific Society of Respiriology, Hong Kong, China, 12/15/12: *Comparison of BEA2180 to tiotropium and placebo via Respimat in patients with COPD*. **Roger Abrahams, MD**.

Roger Abrahams, Petra Moroni-Zentgraf, Joe Ramsdell, et al. Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD. *Respiratory Medicine*. Vol 107, issue 6; June, 2013; p 854-862

CLINICAL RESEARCH,
PRINCIPAL
INVESTIGATOR:
Morgantown Pulmonary
Clinical Research

2015-Present GSK: “Study MEA117113: Mepolizumab VS. Placebo as add-on treatment for fequently exacerbating COPD patients characterized by eosinophil level”

2015-Present Boehringer Ingelheim: “ A randomised, double-blind, active-controlled parallel group study to elvaluate the effect

of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared with tiotropium on Chronic Obstructive Pulmonary Disease (COPD) exacerbation in patients with severe to very severe COPD. (DYNAGITO) (protocol #1237.19)

2015–Present Pearl: “A Randomized, double-Blind, Multi-Center, Parallel Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbation over a 52-week Treatment Period in Subjects With Moderate to Very Severe COPD.” (protocol #PT10005-01)

2015–Present Pearl: “A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003 and PT009 compared with Symbicort Turbuhaler as and Active Control in subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease.” (protocol #PT010006-00)

2014-Present Astra Zeneca “A randomised, double-blind, double dummy, placebo-controlled, parallel group, multicentre, phase III study to evaluate the efficacy and safety of 3 doses of benralizumab (MEDI-563) in patients with severe to very severe Chronic Obstructive Pulmonary disease (COPD) with a history of COPD exacerbations” (TERRANOVA) (protocol #D3251C00004)

2014-2015 GSK “A 4-Week Study to Evaluate Four Doses of Umeclidinium Bromide in Combination with Fluticasone Furoate in COPD Subjects with an Asthmatic Component”(protocol # 200699).

2014 Boehringer-Ingelheim: “A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy of 12 weeks of once daily treatment of two doses of orally inhaled tiotropium + olodaterol fixed dose combination (delivered by the Respimat® inhaler) in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)” [OTEMTO™2] (protocol # 1237.26).

2013-2014 GSK: “A study to compare the addition of umeclidinium bromide (UMEC) to fluticasone furoate (FF)/vilanterol (VI), with placebo plus FF/VI in subjects with Chronic Obstructive Pulmonary Disease (COPD)” (protocol # 200109).

2012-2014 **Coordinating Investigator**, Boehringer-Ingelheim:

"A randomize, double-blind, parallel group study to assess efficacy and safety of 12 weeks of once daily treatment of orally inhaled Olodaterol 5 mcg (delivered by the Respimat inhaler) added to tiotropium 18 mcg (delivered by the HandiHaler) compared to placebo (delivered by the Respimat inhaler) added to tiotropium 18 mcg (delivered by the HandiHaler) in patients with chronic obstructive pulmonary disease (COPD)" (protocol #1222.51).

2012- 2013 Forest Research: A phase III, long-term, randomize, double blind, extension study of the efficacy, safety and tolerability of 2 fixed dose combinations of Acclidinium Bromide/Formoterol Fumarate, Acclidinium Bromide, Formoterol Fumarate and placebo for 28 weeks treatment in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD)" (protocol #LAC-MD-36).

2012- 2014 Boehringer Ingelheim: "A randomize, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + Olodaterol fixed dose combination (2.5 mcg/5 mcg; 5 mcg/5 mcg) (delivered by the Respimat inhaler) compared with the individual components (2.5 mcg and 5 mcg tiotropium, 5 mcg Olodaterol) (delivered by the Respimat inhaler) in patients with chronic obstructive pulmonary disease (COPD). [TOnado TM 1]" (protocol #1237.5).

2012 PEARL Therapeutics: "A randomize, double blind, (test products), chronic dosing (7 days), four-period, eight treatment, incomplete block, crossover, multicenter study to assess efficacy and safety of 5 doses of PT 003, one dose of PT 001 and one dose of PT 005 in patients with moderate to severe COPD, compared with Spiriva HandiHaler (tiotropium bromide 18 mcg, open label) as active-controlled" (protocol #PT 003005-00).

2011-2012 Forest Laboratories: "A phase III, randomized, double blind, placebo controlled study evaluating the efficacy, safety, and tolerability of 2 fixed dose combination of Acclidinium Bromide/Formoterol Fumarate Compared with Acclidinium Bromide, Formoterol Fumarate and placebo for 24 weeks in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD)" (protocol #LAC-MD-31).

2011-2012 Glaxo SmithKline: "A 52 week, multicenter, randomize, double blind, parallel group, placebo controlled study to evaluate the safety and tolerability of GSK 573719 125 mcg once daily alone and in combination with GW 642444 25 mcg once daily via novel dry powder inhaler (nDPI) in subjects with chronic obstructive pulmonary disease (COPD)" (protocol #DB 2113359).

2011-2012 Glaxo SmithKline: "A multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with tiotropium over 24 weeks in subjects with COPD (protocol #DB 211-3374)."

2010- 2012 Glaxo SmithKline: "A long-term safety study of GSK573719 alone and in combination with GW642444 compared with placebo in subjects with COPD (protocol #DB2113359) ".

2009-2010 Boehringer-Ingelheim: "Phase III, one-year, randomized, open-label safety and patient acceptability study of Combivent® Respimat® (ipratropium bromide and albuterol sulfate) (20/100 mcg) Inhalation Spray in comparison to Combivent® Inhalation Aerosol (36/206 mcg) and the free combination of Atrovent® HFA (ipratropium bromide HFA) Inhalation Aerosol (34 mcg) and albuterol HFA inhalation aerosol (180 mcg) in adults with chronic obstructive pulmonary disease (COPD) (protocol #BI 1012.62)"

2009-2010 Pifzer: "A Phase 2B, parallel, double blind, double dummy, active comparator and placebo controlled study to investigate the Safety, Toleration and Efficacy of 6-week QD administration of PF-00610355 CRC-749 DPI in patients with moderate COPD (protocol #A7881013)".

2009-2010 Glaxo SmithKline: "A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared with Placebo in Subjects with Chronic Obstructive Pulmonary Disease (COPD) HZC112207".

2009-2010 Boehringer-Ingelheim: "Randomize, double blind, placebo controlled, parallel group study to assess the efficacy and safety of 48 weeks of once daily treatment of orally inhaled BI 1744 CL (5 mcg [2 actuations of 2.5 mcg] and 10 mcg [2 actuations of 5 mcg]) delivered by the Respimat inhaler, in patients with chronic obstructive pulmonary disease (COPD) (protocol #1222.12)".

2009-2010 Glaxo SmithKline: "A Randomized, Double-Blind, Parallel-Group, 16-Week Study to Evaluate the Effect of Fluticasone Propionate/Salmeterol DISKUS™ 250/50mcg BID and Placebo on Arterial Stiffness in Subjects with Chronic Obstructive Pulmonary Disease (COPD) (protocol #ADC112355) ".

2007-2009 Glaxo SmithKline: "A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone

Propionate/Salmeterol DISKUS Combination Product (FSC)
250/50 mcg BID and Fluticasone Propionate (FP)
DISKUS 250 mcg BID in Treatment of Subjects with Asthma
(protocol #ADA109057)".

2007-2009 **Coordinating Investigator**, Boehringer-Ingelheim:
"A multinational, randomized, double-blind, placebo- and active-
controlled, parallel group efficacy and safety comparison over 24
weeks of three doses (50 µg , 100 µg, 200 µg) of BEA 2180 to
tiotropium 5 µg and placebo delivered by the Respimat® inhaler in
patients with chronic obstructive pulmonary disease (COPD)
(protocol #1205.14)".

2008-2009 Boehringer-Ingelheim: "Randomize, double blind,
parallel group study to assess the efficacy and safety of 4 weeks of
once daily treatment of 3 doses of orally inhaled BI 1744CL, each
in fixed dose combination with 5 mcg tiotropium bromide
(delivered by the Respimat inhaler) compared with 5 mcg
tiotropium bromide mono product (delivered by the Respimat
inhaler) in patients with COPD (protocol number BI 1237.4)".

2008-2009 Glaxo SmithKline: "A Randomize, Double
Blind, Double Dummy, Parallel Group 12 Week Comparison of
the Efficacy and Safety of Fluticasone Propionate/Salmeterol
Hydrofluoroalkane 134 a Metered-Dose Inhaler 230/42 Mcg Twice
Daily with Fluticasone Propionate/Salmeterol Diskus 250/50 Mcg
Twice Daily in Subjects with COPD (Protocol #ADC 111117) ".

2007-2008 Boehringer-Ingelheim: "A 24 Week (+24 Week
Extension), Randomize, Placebo Controlled (Only First 12 Week
Period), Double Blind, Parallel Group, Efficacy and Safety
Comparison of Tiotropium/Salmeterol (7.5 Mcg/25 Mcg)
Inhalation Powder in the Morning (PE Capsule Via
Tiotropium/Salmeterol HandiHaler), Tiotropium (18 Mcg)
Inhalation Powder in the Morning (Gelatin Capsule Via Spiriva
HandiHaler), Salmeterol Inhalation (25 Mcg) Powder in the
Morning and Evening (PE Capsule Via Tiotropium/Salmeterol
HandiHaler) and Tiotropium/Salmeterol (7.5 Mcg/25 Mcg)

Inhalation Powder in the Morning (PE Capsule Via
Tiotropium/Salmeterol HandiHaler) Plus Salmeterol (25 Mcg)
Inhalation Powder in the Evening (PE Capsule Via
Tiotropium/Salmeterol HandiHaler) in Patients with COPD
(Protocol #1184.15) ".

2007-2008 Novartis: "A 12 Week Treatment, Multicenter,
Randomize, Double Blind, Placebo Controlled, Parallel Group
Study to Assess the Efficacy and Safety of Indacaterol (150 Mcg
O. D.) In Patients with Chronic Obstructive Pulmonary Disease
(Protocol #CQAB

149B 2346) ".

2007 Dey: "A Randomize, Open Label, 2-Way Crossover Trial of Formoterol Fumarate Inhalation Solution (20 Mcg) and Combivent Inhalation Aerosol (Ipratropium Bromide 18 Mcg/Albuterol Sulfate 103 Mcg) in the Treatment of Patients with Chronic Obstructive Pulmonary Disease (Protocol #201-081)".

2006-2007 Sepracor: "A Two-Week, Randomized, Modified-Blind, Double-Dummy, Parallel-Group Efficacy and Safety Study of Arformoterol Tartrate Inhalation Solution Twice-Daily, Tiotropium Inhalation Powder Once-Daily, and

Arformoterol Tartrate Inhalation Solution Twice-Daily and Tiotropium Inhalation Powder Once-Daily (Dosed Sequentially) in Subjects with Chronic Obstructive Pulmonary Disease."(COPD) (Protocol 091-902).

2006-2007 Boehringer Ingelheim: "A comparison of ipratropium bromide/salbutamol delivered by the Respimat® inhaler to COMBIVENT® Inhalation Aerosol and ipratropium bromide delivered by the Respimat® in a 12-week, double-blind, safety and efficacy study in adults with chronic obstructive pulmonary disease." (COPD) (Protocol 1012.56).

2006-2007 Adams: "A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Dose-Ranging Study of Erdosteine for the Treatment of Stable Chronic Bronchitis Associated with Chronic Obstructive Pulmonary disease." (Chronic Bronchitis) (Protocol ERD-CB-01-2005).

(Prior Studies Upon Request)

**TEACHING
APPOINTMENTS:**

Clinical Assistant Professor Department of Medicine Section of Pulmonary Diseases West Virginia University Medical School Morgantown, WV 26505	2001-Present
Clinical Instructor Department of Medicine Section of Pulmonary Diseases West Virginia University Medical School Morgantown, WV 26505	1987-2001
Visiting Professor Department of Pulmonary Medicine	9/86 & 8/87

Autonomous University of Guadalajara
Medical School, Mexico

Instructor: Department of Medicine 1984-1985
Division of Pulmonary Medicine
University of Massachusetts Medical School
Worcester, MA

Instructor: Quinsigamond Community 1984-1985
College, Department of Respiratory Therapy
Worcester, MA

HONORS/AWARDS:

Annual Scientific Essay Contest 1979
Long Island Jewish Medical Center
and Queens Hospital: Third Prize

"Best Medical Student Award" 1978
Class of 1978

Phi Kappa Phi National Honor Society 1973

Blue Key National Honor Society 1973

"Who's Who in American Universities
and Colleges" 1973

CERTIFICATIONS:

American Board of Internal Medicine 1988
Sub-specialty Board in Pulmonary Diseases

NIOSH Certified "B" Reader 1986

American Board of Internal Medicine 1983

Advanced Cardiac Life Support 1980

Federal Licensing Exam - New York 1979

Examination Commission for 1977
Foreign Medical Graduates

LICENSURE:

Pennsylvania 1988

West Virginia 1985

Massachusetts 1984

New York 1979

**PROFESSIONAL
SOCIETIES:**

American Thoracic Society
Fellow, American College of Chest Physicians

American College of Physicians
West Virginia Thoracic Society
West Virginia Medical Society
Monongalia County Medical Society
Tri State Chest Physicians Association
American Medical Association

EDUCATION:

Medical:	State University of New York at Stonybrook Queens Hospital Center 5th Pathway	1978-1979
	Autonomous University of Guadalajara Mexico; M.D.	1974-1978
Pre-Medical:	Alfred University, NY B.A. Cum Laude - Chemistry	1969-1973

OTHER LANGUAGES: Spanish

PERSONAL INTERESTS:

Photography: First Place and three honorable mentions in Eastman Kodak and Scholastic Magazine Photography Contest

First Place in New York Coliseum International Photography Show Contest.

Scuba Diving

Sailing

Cycling

Backpacking

REFERENCES: Available on request

Updated 02-09-2016

Publications--Roger Abrahams, MD, FCCP

Title	Author	Type	Citation Year	Status	Citation Source
Safety of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat in chronic obstructive pulmonary disease in two 1-year studies	Roland Buhl, Roger Abrahams, Leif Bjermer, Eric Derom, Matjaž Fležar, Jacques Hébert, Antony Veale, *Lars Groenke, *Alan Hamilton, *Kay Tetzlaff, *Lawrence Korducki, *Holger Huisman, *Stella Waitere-Wijker, Lorcan McGarvey	Abstract	2014	Published	European Respiratory Society - 24th Annual Congress
Health Status of Patients with COPD Receiving the Combination of Olodaterol Respimat® and Tiotropium HandiHaler® Compared with Tiotropium: Results from Two Replicate, Randomized, Double-Blind Studies	Richard ZuWallack, *Lisa Allen, *Gemzel Hernandez-Martinez, *Naitee Ting, Roger Abrahams	Abstract	2014	Published	American College of Chest Physicians - CHEST 2014
Combined Use of Olodaterol Respimat® and Tiotropium HandiHaler® Shows Additional Lung Function Improvement in COPD Compared with Tiotropium: Results from Two Randomized, Double-blind Studies	Richard ZuWallack, *Lisa Allen, *Gemzel Hernandez-Martinez, *Naitee Ting, Roger Abrahams	Abstract	2014	Published	American College of Chest Physicians - CHEST 2014
Safety of the Combination of Olodaterol Respimat® and Tiotropium HandiHaler® Compared with Tiotropium: Results from Two Replicate 12-Week Studies	Roger Abrahams, *Lisa Allen, *Gemzel Hernandez-Martinez, *Naitee Ting, Richard ZuWallack	Abstract	2014	Published	American College of Chest Physicians - CHEST 2014
Pooled Safety Analysis of Once-Daily Tiotropium and Olodaterol Fixed-Dose Combination via the Respimat® in Patients with Chronic Obstructive Pulmonary Disease: Two 1-Year Studies	Roland Buhl, Roger Abrahams, Leif Bjermer, Eric Derom, Matjaž Fležar, Jacques Hébert, Antony Veale, *Lars Groenke, *Kay Tetzlaff, *Lawrence Korducki, *Holger Huisman, *Stella Waitere-Wijker, Lorcan McGarvey	Abstract	2014	Published	American College of Chest Physicians - CHEST 2014
Safety of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat in chronic obstructive pulmonary disease in two 1-year studies	Roland Buhl, Roger Abrahams, Leif Bjermer, Eric Derom, Matjaž Fležar, Jacques Hébert, Antony Veale, *Lars Groenke, *Alan Hamilton, *Kay Tetzlaff, *Lawrence Korducki, *Holger Huisman, *Stella Waitere-Wijker, Lorcan McGarvey	Abstract	2014	Published	British Thoracic Society Winter Meeting 2014
Analysis of the efficacy and safety of the fixed-dose combination of tiotropium + olodaterol in patients with COPD by initial disease severity	Stephanie Korn, Roland Buhl, *Lars Grönke, *Lawrence Korducki, *Valeria C Amato, Gary Ferguson, Roger Abrahams	Abstract	2015	Published	Am J Respir Crit Care Med
Analysis of the efficacy and safety of the fixed-dose combination of tiotropium + olodaterol in patients with COPD by previous usage of inhaled corticosteroids	Stephanie Korn, Roland Buhl, *Lars Grönke, *Lawrence Korducki, *Valeria C Amato, Gary Ferguson, Roger Abrahams	Abstract	2015	Published	Am J Respir Crit Care Med

OWCA/DCMWC
 DIRECTOR'S OFFICE
 2016 MAR 15 AM 10:29

Publications--Roger Abrahams, MD, FCCP

Safety of combining olodaterol Respimat® and tiotropium HandiHaler® in African-American patients with COPD: results of pooled data from two randomized, double-blind, active-controlled studies	Roger Abrahams, *Lisa Allen, *Kay Tetzlaff, *Florian Voß, Richard ZuWallack	Abstract	2015	Published	American Thoracic Society - 111th International Conference
Tiotropium plus olodaterol fixed-dose combination therapy provides lung function benefits when compared with tiotropium alone, irrespective of prior treatment with a long-acting bronchodilator: post hoc analyses of two 1-year studies	Roland Buhl, Roger Abrahams, *Lars Grönke, *Lawrence Korducki, Matjaž Fležar, Gary T Ferguson	Abstract	2015	Published	Am J Respir Crit Care Med
Tiotropium + olodaterol fixed-dose combination therapy provides lung-function benefits compared with tiotropium alone in patients with GOLD A/B and C/D chronic obstructive pulmonary disease: post hoc analyses of two 1-year studies	Roland Buhl, Roger Abrahams, *Lars Grönke, *Florian Voß, Matjaž Fležar, Gary T Ferguson	Abstract	2015	Published	Am J Respir Crit Care Med
Inhaled corticosteroid plus long-acting β2-agonist therapy is overused in the treatment of patients with chronic obstructive pulmonary disease: post hoc analyses of two 1-year studies	Henrik Watz, Gary T Ferguson, *Lars Grönke, *Florian Voß, Roger Abrahams, Ronald Buhl	Abstract	2015	Published	Am J Respir Crit Care Med
Characteristics of COPD patients with and without maintenance treatment at baseline, by GOLD stage: TONADO	Stephanie Korn, Roger Abrahams, *Lars Grönke, *Lawrence Korducki, *Valeria C Amatto, Roland Buhl	Abstract	2015	Published	Am J Respir Crit Care Med
Safety of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat in chronic obstructive pulmonary disease in two 1-year studies	Michael Chia, Jim Reid, Roland Buhl, Roger Abrahams, Leif Bjermer, Eric Derom, Matjaž Fležar, Jacques Hebert, Antony Veale, *Lars Groenke, *Alan Hamilton, *Kay Tetzlaff, *Lawrence Korducki, *Holger Huisman, *Stella Waitere-Wijker, Lorcan McGarvey	Abstract	2015	Published	Thoracic Society of Australia and New Zealand - 2015 Annual Scientific Meeting
Predictors of response to treatment from two randomized, double-blind, active-controlled studies combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD	Roger Abrahams, *Lisa Allen, *Emmanuelle Clerisme-Beaty, *Naitee Ting, Richard ZuWallack	Abstract	2015	Published	American Thoracic Society - 111th International Conference
Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life vs placebo	Dave Singh, Gary T. Ferguson, Josef Bolitschek, *Lars Grönke, *Christoph Hallmann, *Nathan Bennett, Roger Abrahams, Olaf Schmidt, Leif Bjermer	Abstract	2015	Published	European Respiratory Society - 25th Annual Congress
Efficacy and safety of once-daily tiotropium and olodaterol fixed-dose combination via Respimat® in COPD	Chris Garvey, Roger Abrahams, Lars Groenke*, Gary Ferguson	Abstract	2015	Presented	American Association of Nurse Practitioners - 2015 National Conference
Tiotropium + Olodaterol Provides Improvements in SGRQ and Dyspnea Compared with Monotherapy Components in Patients with COPD: Results from Four Randomized, Double-Blind Studies	Gary T. Ferguson; *Emmanuelle Clermise-Beaty; *Lars Grönke; *Florian Voß; *Lawrence Korducki; *Nathan Bennett; Roger Abrahams	Abstract	2015	Published	American College of Chest Physicians - CHEST 2015

Publications--Roger Abrahams, MD, FCCP

Effect of Tiotropium + Olodaterol on the Use of NightTime Rescue Medication in Patients with COPD: Results from Four Randomized, Double-Blind Studies	Roger Abrahams; Gary T. Ferguson; *Emmanuelle Clermise-Beaty, * Lars Grönke; *Florian Voß; *Lawrence Korducki; *Nathan Bennett; Roland Buhl	Abstract	2015	Published	American College of Chest Physicians - CHEST 2015
Safety of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat® in chronic obstructive pulmonary disease in two 1-year studies	Roland Buhl, Roger Abrahams, Leif Bjermer, Eric Derom, Matjaž Fležar, Jacques Hébert, Antony Veale, *Lars Grönke, *Alan Hamilton, *Kay Tetzlaff, *Lawrence Korducki, *Holger Huisman, *Stella Waitere-Wijker, Lorcan McGarvey	Abstract	2015	Published	Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin - 56th Kongress
Characteristics of COPD patients with and without maintenance treatment at baseline, by GOLD stage: TONADO	Stephanie Korn, Roger Abrahams, *Lars Grönke, *Lawrence Korducki, *Valeria C Amato, Roland Buhl	Abstract	2015	Published	British Thoracic Society Winter Meeting 2015
Analysis of the efficacy and safety of the fixed-dose combination of tiotropium + olodaterol in patients with COPD by previous usage of inhaled corticosteroids	Stephanie Korn, Roland Buhl, *Lars Grönke, *Lawrence Korducki, *Valeria C Amato, Gary Ferguson, Roger Abrahams	Abstract	2015	Published	British Thoracic Society Winter Meeting 2015
Inhaled corticosteroid plus long-acting β2-agonist therapy is overused in the treatment of patients with chronic obstructive pulmonary disease: post hoc analyses of two 1-year studies	Henrik Watz, Gary T Ferguson, *Lars Grönke, *Florian Voß, Roger Abrahams, Ronald Buhl	Abstract	2015	Published	British Thoracic Society Winter Meeting 2015
Tiotropium plus olodaterol fixed-dose combination therapy provides lung function benefits when compared with tiotropium alone, irrespective of prior treatment with a long-acting bronchodilator: post hoc analyses of two 1-year studies	Roland Buhl, Roger Abrahams, *Lars Grönke, *Lawrence Korducki, Matjaž Fležar, Gary T Ferguson	Abstract	2015	Published	British Thoracic Society Winter Meeting 2015
Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)	R Buhl, F Maltais, R Abrahams, L Bjermer, E Derom, G Ferguson, M Fležar, J Hébert, L McGarvey, E Pizzichini, J Reid, A Veale, *L Grönke, *A Hamilton, *L Korducki, *K Tetzlaff, *S Waitere-Wijker, H Watz, E Bateman	Primary Manuscript	2015	Published	Eur Respir J
Efficacy and safety of combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD: results of two randomized, double-blind, active-controlled studies	Richard ZuWallack, *Lisa Allen, *Gemzel Hernandez-Martinez, *Naitee Ting, Roger Abrahams	Primary Manuscript	2014	Published	Int J Chron Obstruct Pulmon Dis
Tiotropium + olodaterol shows clinically meaningful improvements in quality of life	Dave Singh, Gary T Ferguson, Josef Bolitschek, *Lars Grönke, *Christoph Hallman, *Nathan Bennett, Roger Abrahams, Olaf Schmidt, Leif Bjermer	Primary Manuscript	2015	Published	Respir Med
Efficacy and safety of ipratropium bromide/albuterol inhaled via Respimat(R) or MDI	ZuWallack R, De Salvo M, Kaelin T, Bateman E, Park C, Abrahams R, Faisal F, Sachs P, Pudi K, *Zhao Y, *Wood C	Primary Manuscript	2010	Completed	Respir Med

Publications--Roger Abrahams, MD, FCCP

Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis	Ferguson GT, Flezar M, Korn S, *Korducki L, *Groenke L, Abrahams R, Buhl R	Secondary Manuscript	2015	Published	Adv Ther
Safety of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat in chronic obstructive pulmonary disease in two 1-year studies	Roland Buhl, Roger Abrahams, Leif Bjermer, Eric Derom, Matjaž Fležar, Jacques Hébert, Antony Veale, *Lars Groenke, *Alan Hamilton, *Kay Tetzlaff, *Lawrence Korducki, *Holger Huisman, *Stella Waitere-Wijker, Lorcan McGarvey	Poster	2014	Presented	European Respiratory Society - 24th Annual Congress
Safety of the Combination of Olodaterol Respimat® and Tiotropium HandiHaler® Compared with Tiotropium: Results from Two Replicate 12-Week Studies	Roger Abrahams, *Lisa Allen, *Gemzel Hernandez-Martinez, *Naitee Ting, Richard ZuWallack	Poster	2014	Presented	American College of Chest Physicians - CHEST 2014
Health Status of Patients with COPD Receiving the Combination of Olodaterol Respimat® and Tiotropium HandiHaler® Compared with Tiotropium: Results from Two Replicate, Randomized, Double-Blind Studies	Richard ZuWallack, *Lisa Allen, *Gemzel Hernandez-Martinez, *Naitee Ting, Roger Abrahams	Poster	2014	Presented	American College of Chest Physicians - CHEST 2014
Pooled Safety Analysis of Once-Daily Tiotropium and Olodaterol Fixed-Dose Combination via the Respimat® in Patients with Chronic Obstructive Pulmonary Disease: Two 1-Year Studies	Roland Buhl, Roger Abrahams, Leif Bjermer, Eric Derom, Matjaž Fležar, Jacques Hébert, Antony Veale, *Lars Groenke, *Kay Tetzlaff, *Lawrence Korducki, *Holger Huisman, *Stella Waitere-Wijker, Lorcan McGarvey	Poster	2014	Presented	American College of Chest Physicians - CHEST 2014
Safety of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat® in chronic obstructive pulmonary disease in two 1-year studies	Roland Buhl, Roger Abrahams, Leif Bjermer, Eric Derom, Matjaž Fležar, Jacques Hébert, Antony Veale, *Lars Grönke, *Alan Hamilton, *Kay Tetzlaff, *Lawrence Korducki, *Holger Huisman, *Stella Waitere-Wijker, Lorcan McGarvey	Poster	2014	Presented	British Thoracic Society Winter Meeting 2014
Analysis of the efficacy and safety of the fixed-dose combination of tiotropium + olodaterol in patients with COPD by initial disease severity	Stephanie Korn, Roland Buhl, *Lars Grönke, *Lawrence Korducki, *Valeria C Amato, Gary Ferguson, Roger Abrahams	Poster	2015	Presented	American Thoracic Society - 111th International Conference
Analysis of the efficacy and safety of the fixed-dose combination of tiotropium + olodaterol in patients with COPD by previous usage of inhaled corticosteroids	Stephanie Korn, Roland Buhl, *Lars Grönke, *Lawrence Korducki, *Valeria C Amato, Gary Ferguson, Roger Abrahams	Poster	2015	Presented	American Thoracic Society - 111th International Conference
Tiotropium + olodaterol fixed-dose combination therapy provides lung function benefits when compared with tiotropium alone, irrespective of prior treatment with a long-acting bronchodilator: post hoc analyses of two 1-year studies	Roland Buhl, Roger Abrahams, *Lars Grönke, *Lawrence Korducki, Matjaž Fležar, Gary T Ferguson	Poster	2015	Presented	American Thoracic Society - 111th International Conference

Publications--Roger Abrahams, MD, FCCP

Tiotropium + olodaterol fixed-dose combination therapy provides lung-function benefits compared with tiotropium alone in patients with GOLD A/B and C/D chronic obstructive pulmonary disease: post hoc analyses of two 1-year studies	Roland Buhl, Roger Abrahams, *Lars Grönke,* Florian Voß, Matjaž Fležar, Gary T Ferguson	Poster	2015	Presented	American Thoracic Society - 111th International Conference
Inhaled corticosteroid plus long-acting β 2-agonist therapy is overused in the treatment of patients with chronic obstructive pulmonary disease: post hoc analyses of two 1-year studies	Henrik Watz, Gary T Ferguson, *Lars Grönke, *Florian Voß, Roger Abrahams, Ronald Buhl	Poster	2015	Presented	American Thoracic Society - 111th International Conference
Characteristics of COPD patients with and without maintenance treatment at baseline, by GOLD stage: TONADO	Stephanie Korn, Roger Abrahams, *Lars Grönke, *Lawrence Korducki, *Valeria C Amatto, Roland Buhl	Poster	2015	Presented	American Thoracic Society - 111th International Conference
Safety of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat in chronic obstructive pulmonary disease in two 1-year studies	Michael Chia, Roland Buhl, Roger Abrahams, Leif Bjermer, Eric Derom, Matjaž Fležar, Jacques Hebert, Antony Veale, *Lars Groenke, *Alan Hamilton, *Kay Tetzlaff, *Lawrence Korducki, *Holger Huisman, *Stella Waitere-Wijker, Lorcan McGarvey	Poster	2015	Presented	Thoracic Society of Australia and New Zealand - 2015 Annual Scientific Meeting
Safety of combining olodaterol Respimat® and tiotropium HandiHaler® in African-American patients with COPD: results of pooled data from two randomized, double-blind, active-controlled studies	Roger Abrahams, *Lisa Allen, *Kay Tetzlaff, *Florian Voß, Richard ZuWallack	Poster	2015	Presented	American Thoracic Society - 111th International Conference
Predictors of response to treatment from two randomized, double-blind, active-controlled studies combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD	Roger Abrahams, *Lisa Allen, *Emmanuelle Clerisme-Beaty, *Naitee Ting, Richard ZuWallack	Poster	2015	Presented	American Thoracic Society - 111th International Conference
Safety of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat® in chronic obstructive pulmonary disease in two 1-year studies	Roland Buhl, Roger Abrahams, Leif Bjermer, Eric Derom, Matjaž Fležar, Jacques Hébert, Antony Veale, *Lars Grönke, *Alan Hamilton,*Kay Tetzlaff,*Lawrence Korducki, *Holger Huisman, *Stella Waitere-Wijker, Lorcan McGarvey	Poster	2015	Presented	Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin - 56th Kongress
Efficacy and safety of once-daily tiotropium and olodaterol fixed-dose combination via Respimat® in COPD	Chris Garvey, Roger Abrahams, Lars Groenke*, Gary Ferguson	Poster	2015	Presented	American Association of Nurse Practitioners - 2015 National Conference
Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo	Dave Singh, Gary T Ferguson, Josef Bolitschek, *Lars Grönke, *Christoph Hallmann, *Nathan Bennett, Roger Abrahams, Olaf Schmidt, Leif Bjermer	Poster	2015	Presented	European Respiratory Society - 25th Annual Congress
Tiotropium + Olodaterol Provides Improvements in SGRQ and Dyspnea Compared with Monotherapy Components in Patients with COPD: Results from Four Randomized, Double-Blind Studies	Gary T. Ferguson; *Emmanuelle Clermise-Beaty; *Lars Grönke; *Florian Voß; *Nathan Bennett; Roger Abrahams	Poster	2015	Presented	American College of Chest Physicians - CHEST 2015

Publications--Roger Abrahams, MD, FCCP

Effect of Tiotropium + Olodaterol on the Use of Night-Time Rescue Medication in Patients with COPD: Results from Four Randomized, Double-Blind Studies	Roger Abrahams; Gary T. Ferguson; *Emmanuelle Clermise-Beaty, * Lars Grönke; *Florian Voß; *Lawrence Korducki; *Nathan Bennett; Roland Buhl	Poster	2015	Presented	American College of Chest Physicians - CHEST 2015
Characteristics of COPD patients with and without maintenance treatment at baseline, by GOLD stage: TONADO	Stephanie Korn, Roger Abrahams, Lars Grönke, Lawrence Korducki, Valeria C Amatto, Roland Buhl	Poster	2015	Presented	British Thoracic Society Winter Meeting 2015
Inhaled corticosteroid plus long-acting B2-agonist therapy is overused in the treatment of patients with chronic obstructive pulmonary disease: post hoc analyses of two 1-year studies	Henrik Watz, Gary T Ferguson, Lars Grönke, Florian Voß, Roger Abrahams, Ronald Buhl	Poster	2015	Presented	British Thoracic Society Winter Meeting 2015
Tiotropium plus olodaterol fixed-dose combination therapy provides lung function benefits when compared with tiotropium alone, irrespective of prior treatment with a long-acting bronchodilator: post hoc analyses of two 1-year studies	Roland Buhl, Roger Abrahams, Lars Grönke, Lawrence Korducki, Matjaž Fležar, Gary T Ferguson	Poster	2015	Presented	British Thoracic Society Winter Meeting 2015
Characteristics of COPD patients with and without maintenance treatment at baseline, by GOLD stage: TONADO	Stephanie Korn, Roger Abrahams, Lars Grönke, Lawrence Korducki, Valeria C Amatto, Roland Buhl	Poster	2015	Presented	British Thoracic Society Winter Meeting 2015
Inhaled corticosteroid plus long-acting B2-agonist therapy is overused in the treatment of patients with chronic obstructive pulmonary disease: post hoc analyses of two 1-year studies	Henrik Watz, Gary T Ferguson, Lars Grönke, Florian Voß, Roger Abrahams, Ronald Buhl	Poster	2015	Presented	British Thoracic Society Winter Meeting 2015
Tiotropium plus olodaterol fixed-dose combination therapy provides lung function benefits when compared with tiotropium alone, irrespective of prior treatment with a long-acting bronchodilator: post hoc analyses of two 1-year studies	Roland Buhl, Roger Abrahams, Lars Grönke, Lawrence Korducki, Matjaž Fležar, Gary T Ferguson	Poster	2015	Presented	British Thoracic Society Winter Meeting 2015
Combined Use of Olodaterol Respimat® and Tiotropium HandiHaler® Shows Additional Lung Function Improvement in COPD Compared with Tiotropium: Results from Two Randomized, Double-blind Studies	Richard ZuWallack, *Lisa Allen, *Gemzel Hernandez-Martinez, *Naitee Ting, Roger Abrahams	Presentation	2014	Presented	American College of Chest Physicians - CHEST 2014
Analysis of the efficacy and safety of the fixed-dose combination of tiotropium + olodaterol in patients with COPD by previous usage of inhaled corticosteroids	Lorcan McGarvey, Stephanie Korn, Roland Buhl, *Lars Groenke, *Lawrence Korducki, *Valeria C Amatto, Gary T Ferguson, Roger Abrahams	Presentation	2015	Presented	British Thoracic Society Winter Meeting 2015